@entity1175 ( @entity1175 ) and @entity12107 ( @entity12107 ) lead to @entity170 in adult @entity1 . We were interested in whether response to treatment of these conditions by @entity251 could be predicted by in vivo quantitative bone SPECT (QBS) measurement of bone turnover and whether @entity251 administration affects @entity79 ( @entity79 ) in these subjects. METHODS: In vivo QBS and @entity79 measurements were performed in the @entity3570 ( @entity3570 ) and femoral neck (FN) of 29 young @entity1 with @entity1175 and 16 young @entity1 with @entity12107 . In vivo QBS and @entity79 values in these @entity1 were compared to the values obtained from 27 age-matched normal controls. The effect of @entity251 treatment was determined by measuring changes in QBS and @entity79 , before and after treatment of 22 @entity1 with @entity1175 and of all 16 @entity1 with @entity12107 . Seven @entity1 with @entity1175 were not treated. RESULTS: In vivo QBS values in @entity1 with @entity1175 were significantly higher than those in controls (8.44% +/- 2.55%ID/ml compared to 5.63% +/- 1.12%ID/ml x 10(-3), p < 0.001, for the @entity3570 ; and 7.86% +/- 3.01%ID/ml compared to 4.29% +/- 1.25%ID/ml, p < 0.001, for the FN). One year after @entity251 treatment, QBS values in @entity1175 were significantly reduced. Pretreatment @entity79 values in @entity1 with @entity1175 were significantly lower than those in normal subjects (0.77 +/- 0.11 g/cm2 compared to 1.03 +/- 0.14 g/cm2, p < 0.0001, for the @entity3570 ; and 0.89 +/- 0.11 g/cm2 compared to 1.08 +/- 0.18 g/cm2, p < 0.006, for the FN). One year after treatment, @entity79 values increased significantly (0.91 +/- 0.14 g/cm2, p < 0.0001, for the @entity3570 ; and 0.97 +/- 0.11 g/cm2, p < 0.0001, for the FN). The seven untreated young @entity1 with @entity1175 still had significantly lower-than-normal @entity79 values (0.82 +/- 0.08 g/cm2, p < 0.008, for the @entity3570 ; and 0.89 +/- 0.05 g/cm2, p < 0.04, for the FN). In @entity1 with @entity12107 , QBS values were not significantly different from those found in normal controls. The values for @entity79 were significantly lower for both the @entity3570 (p < 0.0001) and the FN (p < 0.001). After treatment, @entity79 values in @entity1 with @entity12107 were still significantly lower than those of normals (p < 0.009 for the @entity3570 ; and p < 0.006 for the FN). CONCLUSION: Young @entity1 with maturation abnormalities show low bone density. @entity1 with @entity1175 and high bone turnover, as revealed by high QBS values, respond to @entity251 treatment. @entity1 with @entity12107 have normal bone turnover and do not respond to @entity251 .

Quantitative bone SPECT in young males with @entity1175 and hypogonadism: implications for treatment of low XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity3570 :: ('MESH:D016135', 'Disease') :: ['lumbar spine', 'LS'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity1175 :: ('MESH:D011628', 'Disease') :: ['Constitutional delayed puberty', 'DP'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD'] @entity12107 :: ('MESH:C562785', 'Disease') :: ['IHH', 'idiopathic hypogonadotropic hypogonadism']
@entity79 :: (MESH:D001847,Disease) :: ['bone mineral density']
